ACCENDRA HEALTH INC/VA/(ACH)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,497 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in ACH
Events flagged as statistical outliers against ACH's own multi-year baseline — not fixed dollar thresholds.
ACH Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for ACCENDRA HEALTH INC/VA/ (ACH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ACH at 30.3/100 on a 32-signal composite quality model, placing it at rank #2,497 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (3.1) and free cash flow (14.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), ACCENDRA HEALTH INC/VA/ reports quarterly revenue of $613.2M, net income of $-89.1M, free cash flow of $-73.6M. Top institutional holders of ACH by reported 13-F value include Coliseum Capital Management, BlackRock, BANK OF AMERICA, based on the most recent SEC filings. ACH trades on the NYSE exchange and files with the SEC under CIK 75252. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ACCENDRA HEALTH INC/VA/ directly from SEC EDGAR. ACCENDRA HEALTH INC/VA/'s 13F Pro composite quality score has ranged between 28 and 49 since 2026, currently 30.3 — a declining long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q2 2026
$613.2M
Net Income
Q2 2026
$-89.1M
Free Cash Flow
Q2 2026
$-73.6M
ROIC
Q2 2026
-12.0%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+3.1% YoYNet Income
-203.5% YoYOperating Income
+112.6% YoYEPS (Diluted)
-202.5% YoYTotal Assets
-47.3% YoYTotal Debt
+11.3% YoYOp. Cash Flow
Free Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.76B +3.1% | $2.68B +5.0% | $2.55B -74.4% | $9.96B +1.7% | $9.79B +15.4% | $8.48B |
| Net Income | $-1.10B -203.5% | $-362.7M -778.2% | $-41.3M -284.5% | $22.4M -89.9% | $221.6M +641.8% | $29.9M |
| Operating Income | $27.5M +112.6% | $-217.7M -263.4% | $133.2M -6.8% | $142.9M -61.2% | $368.5M +80.5% | $204.1M |
| EPS (Diluted) | $-14.31 -202.5% | $-4.73 -792.5% | $-0.53 -282.8% | $0.29 -90.1% | $2.94 +525.5% | $0.47 |
| Total Assets | $2.45B -47.3% | $4.66B -8.6% | $5.09B -5.4% | $5.39B +52.3% | $3.54B +6.0% | $3.34B |
| Total Debt | $2.05B +11.3% | $1.84B -12.2% | $2.10B -16.1% | $2.50B +163.9% | $947.5M -11.1% | $1.07B |
| Operating Cash Flow | — | $161.5M -78.2% | $740.7M +127.9% | $325.0M +161.7% | $124.2M -63.4% | $339.2M |
| Free Cash Flow | — | $-8.8M -101.5% | $568.3M +240.5% | $166.9M +100.6% | $83.2M -70.3% | $280.0M |
Get alerted when ACH's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ACCENDRA HEALTH INC/VA/ including:
Top Institutional Holders of ACH
Coliseum Capital Management, LLC
$44.8M13,100,807 shBlackRock, Inc.
$18.8M5,504,102 shBANK OF AMERICA CORP /DE/
$12.9M3,775,525 shVANGUARD CAPITAL MANAGEMENT LLC
$10.6M3,087,931 shD. E. Shaw & Co., Inc.
$10.5M3,081,407 shCHARLES SCHWAB INVESTMENT MANAGEMENT INC
$9.9M2,888,058 shInvenomic Capital Management LP
$9.6M2,812,474 shMARSHALL WACE, LLP
$8.8M2,582,579 shPARADIGM CAPITAL MANAGEMENT INC/NY
$8.7M2,536,699 shVANGUARD PORTFOLIO MANAGEMENT LLC
$6.9M2,030,956 sh
| Fund | Value | Shares |
|---|---|---|
| Coliseum Capital Management, LLC | $44.8M | 13,100,807 |
| BlackRock, Inc. | $18.8M | 5,504,102 |
| BANK OF AMERICA CORP /DE/ | $12.9M | 3,775,525 |
| VANGUARD CAPITAL MANAGEMENT LLC | $10.6M | 3,087,931 |
| D. E. Shaw & Co., Inc. | $10.5M | 3,081,407 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $9.9M | 2,888,058 |
| Invenomic Capital Management LP | $9.6M | 2,812,474 |
| MARSHALL WACE, LLP | $8.8M | 2,582,579 |
| PARADIGM CAPITAL MANAGEMENT INC/NY | $8.7M | 2,536,699 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $6.9M | 2,030,956 |
Companies Similar to ACH
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Huntsman CORP
INTEGRA LIFESCIENCES HOLDINGS CORP
DENTSPLY SIRONA Inc.
AdaptHealth Corp.
Chemours Co
QuidelOrtho Corp
PERRIGO Co plc
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ACH on your watchlist
Track score changes the day ACCENDRA HEALTH INC/VA/ files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ACH a good stock to buy?
13F Pro's AI-powered analysis of ACCENDRA HEALTH INC/VA/ (ACH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ACH are available on the ACH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ACH is classified as a small company.
Which hedge funds own ACH?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ACH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ACCENDRA HEALTH INC/VA/'s investment landscape.